Kurve Therapeutics
Bypassing the Blood-Brain Barrier
Overview
Rialto Markets
08/03/2022
08/03/2023
$580
$50,000,000
$580
Equity - Common
Series A
RegA+
$5.80
$291,787,299
2019
Healthcare & Pharmaceuticals
HealthTech
B2B
Medium
High
Balance Sheet
|
Cash and Cash Equivalents |
$373,804 |
|
Accounts and Notes Receivable |
$15,000 |
| Total Assets |
$640,574 |
|
Accounts Payable & Accrued Liabilities |
$28,331 |
|
Long Term Debt |
$507,500 |
|
Total Liabilities |
$606,726 |
|
Total Stockholders' Equity |
$33,848 |
| Total Liabilities and Equity |
$640,574 |
Statement of Comprehensive Income Information
|
Total Revenues |
$70,700 |
|
Costs & Expenses Applicable to Rev |
$128,344 |
| Net Income |
$-65,427 |
|
Earnings Per Share - Basic |
$0.00 |
|
Earnings Per Share - Diluted |
$0.00 |
Upgrade to gain access
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Ratings 
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Analyst Report
No company has been able to develop an FDA-approved treatment that stops Alzheimer’s in its tracks. Kurve Therapeutics has the potential to change that with its potentially groundbreaking device. But its long road to FDA approval and its inexperienced team may threaten the company’s survival.
Upgrade to view full report
Founder Profile
Kurve Therapeutics Founder Marc Giroux on Treating Alzheimer’s and More
The central nervous system (CNS) disorder umbrella houses a number of familiar names, like Alzheimer’s, Parkinson’s, and multiple sclerosis. These conditions are often life-altering to sufferers, and many are incurable. Thankfully, treatments are available, and scientists aren’t done looking for new solutions.Kurve Therapeutics is fighting CNS disorders right up the nose with its patented Controlled Particle Dispersion technology. This intranasal technology delivers drugs noninvasively and painlessly, and it makes treatments more precise and effective. We reached out to founder and CEO Marc Giroux to hear about why he originally started working on the technology and how Kurve Therapeutics overcame assumptions.
Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.